Skip to main content
Innovations Inspired by
life
Search
Menu
Search
Hamburger
Our Company
Who we are
History
Culture
Board of Directors
Leadership Team
OUR RESEARCH
Therapeutic focus
Delivery Technologies
Research Programs
R&D Pipeline
Our Medicines
Xelpros®
Elepsia® XR
Business Development
Strategy
Partner with us
Investors
Who we are
Financials
Annual reports
Presentations
Chairman's Speech
Committees of BOD's
Shareholding pattern
Announcements & Disclosures
Policies & Codes
Listing Information
Board of Directors
FAQ’s
Investors Contact
Go green
IEPF
Media
Press Releases
Presentations
Careers
Overview
Apply Now
Contact Us
Media
»
Press Releases
Media
Press Releases
Presentations
Press Releases
14-Jun-2017
SPARC Announces Top-line Results of Pivotal Peak Inspiratory Flow (PIF) study and Low Dose Pharmacokinetic (PK) Study for Salmeterol – Fluticasone Dry Powder Inhaler (SPARC DPI)
26-Aug-2016
Announcement - Receipt of reclassification approval from BSE
25-Aug-2016
Announcement - Receipt of reclassification approval from NSE
25-Jul-2016
Update on NCE and NDDS Programs
18-Jul-2016
SPARC Licenses ELEPSIATM XR (Levetiracetam ER Tablets) to Sun Pharma
31-Dec-2015
Update on XELP ROST and Elepsia XRT
25-Sep-2015
SPARC Receives Complete Response Letter (CRL) from USFDA for Levetiracetam NDA
01-Aug-2015
SPARC Receives Complete Response Letter (CRL) from USFDA for Latanoprost NDA
09-Jun-2015
SPARC Licenses Xelpros™ to Sun Pharma
04-Mar-2015
SPARC receives USFDA approval for ELEPSIA XR
Pagination
First page
« First
Previous page
‹‹
Page
1
Current page
2
Page
3
Next page
››
Last page
Last »
